Drug Trial Radar · NCT06977581
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
May 20, 2025
Primary completion
Mar 8, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 75 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 6 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for up to approximately 9.5 months depending on local requirements.
Conditions
- Asthma
Interventions
PF-07275315Drug
subcutaneous injection
PlaceboOther
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12Time frame: Week 12
- Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuationTime frame: Baseline through Week 24
- Clinically significant, treatment-related laboratory abnormalitiesTime frame: Baseline through Week 24
- Clinically significant, treatment-related abnormalities in vital signsTime frame: Baseline through Week 24
- Clinically significant, treatment-related electrocardiogram (ECG) abnormalitiesTime frame: Baseline through Week 24
Locations
137 sites in 15 countries. Site status is shown where the registry gives one.
Velocity Clinical Research, Mobile
Mobile, Alabama · Recruiting
Chandler Clinical Trials
Chandler, Arizona · Recruiting
Antelope Valley Clinical Trials
Lancaster, California · Recruiting
NewportNativeMD, Inc.
Newport Beach, California · Recruiting
California Medical Research Associates
Northridge, California · Recruiting
Allergy and Asthma Associates of Santa Clara Valley Research Center
San Jose, California · Recruiting
Allergy & Asthma Clinical Research
Walnut Creek, California · Recruiting
Colorado ENT & Allergy
Colorado Springs, Colorado · Recruiting
Cpcc-Research Llc
East Point, Georgia · Recruiting
Christie Clinic - University
Champaign, Illinois · Recruiting
Innovo Research - Christie Clinic
Champaign, Illinois · Recruiting
Christie Clinic - Windsor
Champaign, Illinois · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
North Ingalls Building
Ann Arbor, Michigan · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Henderson Clinical Trials
Henderson, Nevada · Recruiting
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey · Recruiting
Circuit Clinical / Impact Medical Allergy, Asthma & Immunology
Riverdale, New Jersey · Recruiting
American Health Research
Charlotte, North Carolina · Recruiting
Clinical Research Of Gastonia
Gastonia, North Carolina · Recruiting
Stern Research Partners, LLC
Huntersville, North Carolina · Recruiting
Toledo Institute of Clinical Research Inc.
Toledo, Ohio · Recruiting
OK Clinical Research
Edmond, Oklahoma · Recruiting
Allergy, Asthma and Clinical Research
Oklahoma City, Oklahoma · Recruiting
Layrek Clinical Research
Tulsa, Oklahoma · Recruiting
Clinical Research Associates of Central PA, LLC
DuBois, Pennsylvania · Recruiting
Clinical Research of Rock Hill
Rock Hill, South Carolina · Recruiting
Premier Research Center, LLC
Hendersonville, Tennessee · Recruiting
South Texas Medical Research Institute, Inc., DBA TTS Research
Boerne, Texas · Recruiting
Horizon Clinical Research Group
Cypress, Texas · Recruiting
Alina Clinical Trials, LLC.
Dallas, Texas · Recruiting
Greater Heights & Memorial Pulmonary and Sleep
Houston, Texas · Recruiting
Houston Pulmonary Sleep and Allergy Associates
Houston, Texas · Recruiting
Metroplex Pulmonary and Sleep Center
McKinney, Texas · Active not recruiting
Clinical Research Partners, LLC
Richmond, Virginia · Recruiting
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina · Recruiting
Fundacion Scherbovsky
Mendoza, Argentina · Recruiting
Instituto de Salud Respiratoria
Mendoza, Argentina · Recruiting
Fundación Respirar
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.